NDA 020892 · Endo Operations
Valstar Preservative Free
Valrubicin · Intravesical
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 7, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Sep 25, 1998
Approved uses
2
Original approval plus efficacy supplements
Registered trials
7
4 Phase 3, 0 recruiting
FAERS reports
178
30 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 31, 2024.
VALSTAR is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. VALSTAR is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. ( 1 )
Mechanism: Valrubicin is an anthracycline that affects a variety of interrelated biological functions, most of which involve nucleic acid metabolism. In cells, it inhibits the incorporation of nucleosides into nucleic acids, causes chromosomal damage, and arrests the cell cycle in G 2 . Although valrubicin does not bind strongly to DNA, valrubicin metabolites interfere with the normal DNA breaking-resealing action of DNA topoisomerase II.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 2, 2013 Supplement 16 · Efficacy Letter
- Sep 25, 1998 Original approval · Type 1 - New Molecular Entity · priority review LabelReviewLetter
1 products under this application
- VALSTAR PRESERVATIVE FREE · VALRUBICIN 40MG/ML · SOLUTION, INTRAVESICAL · Prescription · TE AO
Clinical trials
Interventional ClinicalTrials.gov studies with "Valrubicin" as an intervention, any sponsor and status, largest first.
- Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder CancerPivotal-lookingStatus unknown
Anthra PharmaceuticalsIndustry
NCT00003725 · 300 participants (planned) · Start Dec 1996
Drug: valrubicin · For: Bladder Cancer
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 53 sites in all
- Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)Pivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT01316874 · 90 participants · Start Nov 1993 · Primary completion Apr 1997
Drug: Valrubicin, 800 mg · For: Carcinoma in Situ; Bladder Cancer
Sites: Alabaster, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 39 sites in all
Eastern Cooperative Oncology GroupResearch network
NCT00003129 · 75 participants (planned) · Start Sep 1, 1998 · Primary completion Nov 2002
Drug: valrubicin · For: Bladder Cancer
Sites: Tampa, Florida; Urbana, Illinois; East Orange, New Jersey · 10 sites in all
- Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder CancerPivotal-lookingTerminated
CG Oncology, Inc.Industry
NCT01438112 · 22 participants · Start Mar 2014 · Primary completion Jun 2016
Drug: CG0070 Adenovirus Vector · For: Transitional Cell Carcinoma; Bladder Cancer; Carcinoma in Situ and 1 more
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 7 sites in all
H. Lee Moffitt Cancer Center and Research InstituteAcademic, hospital or other
NCT01606345 · 4 participants · Start Jul 2012 · Primary completion Apr 2016
Drug: Valrubicin · For: Urothelial Carcinoma
Sites: Tampa, Florida
- Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the BladderPivotal-lookingTerminated
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT01310803 · 1 participants · Start May 2011 · Primary completion Jan 2012
Drug: VALSTAR - Maintenance Therapy · For: Carcinoma in Situ; Transitional Cell Carcinoma; Non-muscle Invasive Bladder Cancer
Sites: Phoenix, Arizona; Denver, Colorado; Cumberland, Maryland · 6 sites in all
Anthra PharmaceuticalsIndustry
NCT00003759 · Start Nov 1998
Drug: BCG vaccine; valrubicin · For: Bladder Cancer
Sites: Houston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- underdose26
- bladder instillation procedure24
- accidental exposure to product23
- urge incontinence20
- bladder spasm13
- urinary incontinence11
- pain9
- dysuria8
- burning sensation7
- drug ineffective7
- arthralgia6
- fatigue6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 79 |
| 2014 | 26 |
| 2015 | 15 |
| 2016 | 5 |
| 2017 | 10 |
| 2018 | 18 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Nov 13, 2026
Valstar Preservative Free, Solution, 40 mg/1 mL (NDC 67979-001-01). Discontinuation of the manufacture of the drug
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer.
Asimakopoulos AD, Kochergin M, Colalillo G, et al. · Bladder Cancer 2023 · Systematic Review
- Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R, Selph S, Buckley DI, et al. · J Urol 2017 · Meta-Analysis, Systematic Review
- [Systematic review on conservative treatment options in non-muscle-invasive bladder cancer patients refractory to Bacillus Calmette-Guérin instillation therapy].
Martini T, Wezel F, Löbig N, et al. · Aktuelle Urol 2017 · Systematic Review
- Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review.
Casey RG, Catto JW, Cheng L, et al. · Eur Urol 2015 · Meta-Analysis, Systematic Review
- Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
Steinberg G, Bahnson R, Brosman S, et al. · J Urol 2000 · Clinical Trial, Multicenter Study
- The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion study.
Newling DW, Hetherington J, Sundaram SK, et al. · Eur Urol 2001 · Clinical Trial, Clinical Trial, Phase II
Sponsor: Endo Operations
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.